National Centre for
Pharmacoeconomics
NCPE Ireland
About Us
Current Staff
News
Glossary
Contact Us
Vacancies
Home
Submission Process
HTA Guidelines
Process Flowchart
Submission Templates
Pharmacoeconomic Evaluations
Drugs
Vaccines
Diagnostics and Other Technologies
Publications
Peer Reviewed Papers
Abstracts
Reports
Research
Pharmacoeconomic Research
Education
COVID-19
For Patients
Drugs
:
O
A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
R
S
T
U
V
Z
Obeticholic acid (Ocaliva®)
Obinutuzumab (Gazyvaro®) for Follicular Lymphoma
Obinutuzumab (Gazyvaro®) for Lymphocytic Leukaemia
Obinutuzumab (Gazyvaro®) for previously untreated advanced follicular lymphoma
Ocrelizumab (Ocrevus®) for PPMS
Ocrelizumab (Ocrevus®) for RMS
Ocriplasmin (Jetrea®)
Odevixibat (Bylvay®). HTA ID: 21058
Ofatumumab (Arzerra®) (Previously untreated Chronic Lymphocytic Leukaemia)
Ofatumumab (Arzerra®) (Refractory CLL)
1
2
3
4
Next Page
health check